GSA Capital Partners LLP Sells 269,733 Shares of Taysha Gene Therapies, Inc. $TSHA

GSA Capital Partners LLP trimmed its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 56.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 208,016 shares of the company’s stock after selling 269,733 shares during the period. GSA Capital Partners LLP’s holdings in Taysha Gene Therapies were worth $1,144,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Marex Group plc bought a new position in Taysha Gene Therapies during the second quarter valued at about $29,000. E Fund Management Co. Ltd. bought a new position in Taysha Gene Therapies during the second quarter valued at about $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new position in Taysha Gene Therapies during the third quarter valued at about $40,000. Tower Research Capital LLC TRC increased its stake in Taysha Gene Therapies by 156.5% during the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock valued at $41,000 after acquiring an additional 10,742 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in Taysha Gene Therapies by 51.9% during the second quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company’s stock valued at $43,000 after acquiring an additional 6,350 shares during the period. 77.70% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $4.46, for a total value of $892,000.00. Following the completion of the transaction, the insider directly owned 1,136,410 shares of the company’s stock, valued at approximately $5,068,388.60. This represents a 14.97% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.78% of the company’s stock.

Taysha Gene Therapies Trading Up 0.9%

Shares of TSHA opened at $5.54 on Friday. Taysha Gene Therapies, Inc. has a 1 year low of $2.25 and a 1 year high of $7.30. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23. The stock has a 50 day simple moving average of $5.38 and a 200-day simple moving average of $5.01. The stock has a market cap of $1.59 billion, a PE ratio of -14.58 and a beta of 1.25.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). On average, sell-side analysts predict that Taysha Gene Therapies, Inc. will post -0.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TSHA. Canaccord Genuity Group boosted their price target on Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, April 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Friday, March 27th. Truist Financial raised shares of Taysha Gene Therapies to a “strong-buy” rating in a research note on Wednesday, March 25th. Wall Street Zen cut shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Chardan Capital restated a “buy” rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $11.64.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.